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Cells contain a large pool of non-pumping 
Na/K-ATPase that participates in signal 
transduction. Here, we show that the 
expression of α1 Na/K-ATPase is significantly 
reduced in human prostate carcinoma as well 
as in several human cancer cell lines. This 
down-regulation impairs the ability of Na/K-
ATPase to regulate Src-related signaling 
processes.  Supplement of pNaKtide, a 
peptide derived from α1 Na/K-ATPase, 
reduces activities of Src and Src effectors. 
Consequently, these treatments stimulate 
apoptosis and inhibit growth in cultures of 
human cancer cells. Moreover, 
administration of pNaKtide inhibits 
angiogenesis and growth of tumor xenograft. 
Thus, the new findings demonstrate the in 
vivo effectiveness of pNaKtide, and suggest 
that the defect in Na/K-ATPase-mediated 
signal transduction may be targeted for 
developing new anti-cancer therapeutics.   
 
The Na/K-ATPase was originally discovered 
as an ion pump that is essential for cell vitality 
and provides a means for epithelium to secrete 
and/or absorb solutes and nutrients (1,2). Recent 
studies have revealed that in addition to pumping 
ions across cell membrane, the Na/K-ATPase, 
specifically the α1 isoform, conducts many non-
pumping functions including scaffolding and 
signal transduction.  As a signaling protein, it is 
involved in the formation of membrane 
structures such as tight junction and caveolae 
(3,4).  Moreover, a large fraction of cellular 
Na/K-ATPase is involved in tethering and 
regulating multiple protein and lipid kinases as 
well as membrane receptors (e.g. Src, HER and 
PI3K) in a cell-specific manner (5,6). Recently, 
the α1 Na/K-ATPase/Src receptor complex has 
been identified as one of the central components 
of the α1 Na/K-ATPase-mediated signaling 
transduction (7). In this receptor complex, the 
Src SH2 domain binds to the second cytosolic 
domain, while Src kinase domain interacts with 
the nucleotide binding (N) domain of the α1 
subunit.  The latter interaction keeps Src in an 
inactive state (7).  It is important to note that 
normal epithelial cells express about a million 
α1 Na/K-ATPase (roughly five times of Src).  
Thus, the α1 Na/K-ATPase could provide at 
least two ways of regulating cellular Src activity.  
First, it could bind and keep Src in an inactive 
state.   Consistently, when knockout of one copy 
of α1 gene caused a 20 to 30% reduction in 
cellular α1 Na/K-ATPase, it produced more than 
2 fold increase in Src and ERK activities in 
tissues of α1 +/- mice (8).  Second, the formation 
of Na/K-ATPase/Src complex provides a 
functional receptor for endogenous cardiotonic 
steroids (CTS) such as ouabain to regulate 
cellular signaling via Src and Src effectors (7,9). 
Thus, changes in cellular α1 Na/K-ATPase 
would have significant effect on cellular 
signaling events induced by either CTS or other 
growth factors through Src-related pathways. 
Based on the fact that the N domain of α1 
subunit binds and inhibits Src, we have recently 
made pNaKtide from the N domain of human α1 
subunit of Na/K-ATPase (10). Addition of TAT 
leader sequence makes it cell permeable. 
Moreover, a majority of pNaKtide appears to be 
localized in the plasma membrane in cultured 
cells.  Like the N domain of α1 Na/K-ATPase, 
pNaKtide binds and inhibits the Na/K-ATPase-
interacting pool of Src (10).   Consistently, 
pNaKtide blocks the formation of receptor 
Na/K-ATPase/Src complex, but does not alter 
the basal cellular Src activity in cells where the 
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α1 Na/K-ATPase is adequately expressed (10).  
Thus, pNaKtide functions like a receptor 
antagonist, capable of inhibiting ouabain-
induced signal transduction (10).  On the other 
hand, it also works like the α1 Na/K-ATPase 
(11) and is capable of inhibiting Src and Src 
effectors in cells where the expression of Na/K-
ATPase is reduced (10). 
Src regulates cell proliferation/apoptosis, 
migration, and invasion (12,13) and  is involved 
in the progression of many types of cancers (14). 
Once activated by either receptors (e.g., HER 
and androgen receptors) or membrane receptor-
associated proteins (e.g., G proteins) (15-17), 
Src is recruited to cell periphery, focal adhesion 
and tight junction where the α1 Na/K-ATPase 
resides in a high concentration (18-20).  
Previously, we have shown that epithelial cells 
actually contain two functionally distinct pools 
of Na/K-ATPase and that reduction of cellular 
α1 Na/K-ATPase preferentially depletes the Src-
interacting pool of Na/K-ATPase, resulting in an 
elevation in cellular activities of Src and Src 
effectors (8,11,21).  Thus, should the α1 Na/K-
ATPase be down-regulated in cancer cells, this 
could contribute to an increase in kinase activity 
observed in cancers such as prostate carcinoma. 
Conversely, repletion of the α1 Na/K-ATPase or 
application of pNaKtide would antagonize the 
increase in kinase activity, which could inhibit 
tumor growth. To test these hypotheses, we first 
assessed the expression of α1 Na/K-ATPase in 
prostate carcinomas and established cancer cell 
lines, and measured the Na/K-ATPase-mediated 
signal transduction focusing on those that are 
Src-related.  We then tested whether application 
of α1 Na/K-ATPase mimetics such as pNaKtide 
could attenuate the activities of cellular Src and 
Src effectors and inhibit tumor growth.  
 
Experimental Procedures 
 
Materials. Staurosporine was obtained from 
Calbiochem. The following antibodies were 
obtained from Santa Cruz Biotechnology: Src 
(sc-8056), PARP-1 (sc-8007), c-Myc (sc-40), 
ERK (sc-94), phospho-ERK (sc-7383) and 
GAPDH (sc-20357). Antibodies against 
phospho-FAK (Tyr576/577) (3281) and FAK 
(3285) were from Cell Signaling Technology. 
Antibodies against VEGF (Abcam, ab46154) 
and pY418 (Invitrogen, 44-660G) were also 
used. HRP-conjugated anti-rabbit and anti-
mouse secondary antibodies were obtained from 
Santa Cruz Biotechnology. The monoclonal anti-
α1 antibody α6f was obtained from the DSHB at 
the University of Iowa. pNaKtide was 
synthesized with purity above 95%. All other 
chemicals were from Sigma-Aldrich (St. Louis, 
MO). 
Cell Culture. RWPE-1, DU145, LNCaP, PC-3, 
and LLC-PK1 cells were all from American 
Type Culture Collection (ATCC) and grown 
according to ATCC recommendations. DU145 
and PC-3 are prostate cancer cell lines originally 
isolated from metastatic sites in brain and bone, 
respectively. LNCaP cells recapitulate prostate 
cancer progression due to relatively slow growth 
and expression of androgen receptor, while 
RWPE-1 is a non-tumorigenic human prostate 
epithelial cell line. Human umbilical vein 
endothelial cells (HUVEC) and aortic 
endothelial cells (HAEC) were obtained from 
Lonza (Walkersville, MD) and maintained in the 
M199 medium supplemented with 10% FBS, 50 
μg/ml endothelial cell growth supplement (BD 
Biosciences), and 50 μg/ml heparin (BD 
Biosciences). The Na/K-ATPase α1-knockdown 
TCN23-19 cells were developed from LLC-PK1 
cells and maintained as described (11).  
Plasmid Constructs and Transient Transfections. 
The CMV promoter-driven pEYFP-ND1 
construct was generated as described (10). 
Transient transfections were performed using 
LipofectAMINE 2000 (Invitrogen) according to 
the manufacturer's instructions. Expression of 
YFP or YFP-tagged proteins was monitored 
using an Olympus fluorescence microscope. 
Images were processed with SPOT software 
Version 4.60 (Diagnostic Instruments). 
Immunoblot Analysis. Immunoblot analysis was 
performed as described previously (22). 
Following the indicated treatment, the cells were 
rapidly washed with ice-cold PBS. Then the 
cells were lysed in modified ice-cold 
radioimmune precipitation assay (RIPA) buffer 
containing 1% Nonidet P-40, 1% sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 
mM phenylmethylsulfonyl fluoride, 1 mM 
sodium orthovanadate, 1 mM NaF, 10 g/ml 
aprotinin, 10 g/ml leupeptin, and 50 mM Tris-
HCl, pH 7.4. The cell lysates were centrifuged at 
14,000 × g for 15 min, and the supernatants were 
separated by SDS-PAGE, and transferred to the 
Optitran nitrocellulose membranes (Schleicher 
and Schuell, Dassel, Germany). The membranes 
were blocked and probed with specific 
antibodies.  
Measurement of Cell Surface and Endocytosed 
α1 Na/K-ATPase. The surface expression of the 
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α1 Na/K-ATPase was measured by biotinylation 
using the procedures described before (21,23). In 
brief, cultured cells were placed on ice and 
rinsed twice with ice-cold PBS containing 1mM 
EDTA for 5 min, which opens tight junctions 
(23). Then cells were exposed twice to 1.5 
mg/mL EZ-Link Sulfo-NHS-SS-Biotin (Pierce) 
in biotinylation buffer (10 mM triethanolamine, 
150 mM NaCl, pH 9.0) for 25 min at 4 °C. 
Unreacted Sulfo-NHS-SS-Biotin was scavenged 
by incubation with 100 mM glycine buffer (in 
PBS) for 20 min. Cells were then solubilized in 
lysis buffer (1% Triton X-100, 150 mM NaCl, 5 
mM EDTA, 50 mM Tris, pH 7.5) and cell 
lysates were cleared by centrifugation at 14,000g 
for 15 min at 4 °C. Supernatants from different 
treatment groups (based on equal amount of 
protein) were incubated overnight at 4 °C with 
streptavidin-agarose beads (Pierce). The beads 
were then washed twice with lysis buffer, twice 
with high-salt buffer (0.1% Triton X-100, 500 
mM NaCl, 5 mM EDTA, 50 mM Tris, pH7.5), 
and twice with no-salt wash buffer (10 mM Tris, 
pH 7.5). Bound proteins were eluted with 
sodium dodecyl sulfate-containing sample buffer 
and subject to immunoblot analysis as described 
above. 
Endocytosis of the α1 Na/K-ATPase was 
measured using a pulse-chase strategy. 
Biotinylation of cell surface was conducted as 
described above, and unreacted N-
hydroxysulfosuccinimidobiotin was quenched 
with glycine buffer. Then cells were brought 
back to normal culture conditions for 0 or 30 
min at 37 oC, allowing biotinylated surface 1 
Na/K-ATPase to be endocytosed.  The 
endocytosis was terminated by washing cells 
with ice-cold PBS. Afterwards, Tris(2-
carboxyethyl)phosphine  (TCEP, Pierce) 
reducing agent (100 mM TCEP in 50 mM Tris, 
pH 7.4) was added to cells for 30 min at 4 °C to 
clear the remaining cell surface-bound biotin. 
Cell lysates in lysis buffer (1% Triton X-100, 
150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 
7.5) were collected. Equal amount of cell lysates 
(500 µg protein) was incubated with 
streptavidin-agarose beads and bound proteins 
were analyzed by Western blot.     
MTT Assay. MTT assay was performed using the 
MTT cell proliferation assay kit (ATCC). In 
brief, 6,000 cells/well were cultured overnight, 
and then were exposed to different 
concentrations of pNaKtide for the indicated 
time. Ten µl of MTT reagent was added to each 
well for 120 min. The formazan crystal was 
dissolved with detergent, and the OD value was 
measured at 570 nm.  
Apoptosis Assay. Annexin/PI staining and 
TUNEL assay were performed using the 
Vybrant Apoptosis Assay Kit (Invitrogen) and 
the TUNEL Apoptosis Detection Kit (Upstate), 
respectively. Briefly, treated cells were 
resuspended and mixed with Alexa Fluor 488 
annexin V/PI in the annexin-binding buffer. 
Mounted cells were visualized with a Leica 
DMIRE2 confocal microscope. To detect 
apoptotic cells in xenografted tumor tissues, 
TUNEL assay was performed according to the 
manufacturer’s instructions. Slides containing 
formalin-fixed, paraffin-embedded tumor 
sections were depariffinized and then washed 
with PBS for 30 min at 37°C. After incubation 
with proteinase K (Invitrogen), tumor sections 
were mixed with TdT end-labeling cocktail 
(containing Biotin-dUTP, TdT in TdT buffer) for 
60 min at 37°C. After blocking, the tumor 
sections were incubated with avidin-FITC 
solution for 30 min at 37°C. Washed tumor 
sections were further counterstained with PI 
solution and visualized with a Leica DMIRE2 
confocal microscope.  
DU145 Xenograft Tumors in NOD/SCID Mice. 
Animal protocols were approved by the 
Institutional Animal Care and Use Committee at 
the University of Toledo Health Science 
Campus. Tumor xenografts were established by 
s.c. injection of 5 × 106 DU145 cells into the left 
and right flanks of 6-week-old female 
NOD/SCID mice (Charles River). Tumor length 
(L) and width (W) were measured with calipers 
and tumor volume was estimated as V = (L × 
W2)/2. When the tumors reached an average 
volume of 100 mm3, mice were s.c. injected with 
saline or pNaKtide (at doses of 2 mg/kg and 10 
mg/kg body weight) every other day for 5 times.  
Immunostaining of α1 Na/K-ATPase and Active 
Src. Cells cultured on coverslips were fixed for 
15 min with ice-cold methanol, washed with 
PBS for three times and then blocked with 
Signal Enhancer (Invitrogen). The cells were 
then incubated with a mouse anti-Na/K-ATPase 
α1 monoclonal antibody (Millipore) or a rabbit 
anti-pY418 antibody (Invitrogen) in PBS 
containing 1% bovine serum albumin for 1 h at 
room temperature. After three washes with PBS, 
cells were exposed to AlexaFluor 555-
conjugated anti-mouse or AlexaFluor 488-
conjugated anti-Rabbit secondary antibody for 1 
h at room temperature, washed and mounted 
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onto slides. Image visualization was performed 
using a Leica DMIRE2 confocal microscope. 
Immunohistochemical (IHC) Staining and 
Vascularity Analysis. Na/K-ATPase α1 IHC 
staining was performed by US Biomax 
(Rockville, MD) using A human prostate tissue 
microarray (TMA Cat. # PR954, US Biomax), 
which contains 36 cases of prostate carcinoma 
and 8 cases of normal tissues. In brief, prostate 
TMA was depariffinized, hydrated, and 
incubated with 3% H2O2 to block endogenous 
peroxidase. Then, tissue sections were subjected 
to antigen retrieval by using Target Retrieval 
Solution (Dako Cytomation) and blocked with 
normal horse blocking serum. Tissue sections 
were incubated with a mouse monoclonal anti-
Na/K-ATPase α1 antibody (Millipore) solution 
(final concentration 3.3 ng/µl) for 1 hour at room 
temperature. Slides were washed and then 
incubated with ImmPRESS Reagent anti-Mouse 
Ig peroxidase (Vector Laboratories) for 1 hour 
followed by incubation with DAB substrate 
solution (Dako Cytomation) for 5 min. Slides 
were mounted and images were recorded with an 
Olympus light microscope. Specific IHC 
staining of Na/K-ATPase α1 yields brown color 
at site of the target antigen, while Hematoxylin 
counterstaining yields blue color in cell nucleus. 
Two independent pathologists examined α1 
staining intensity and scored each slide three 
times as defined: 0, absent; 1, weak; 2, 
moderate; 3, strong. A mean score was recorded. 
To assess tumor vascularity in the xenograft 
tumor tissues, IHC staining of CD31 in tissue 
sections was performed as aforementioned. A 
goat polyclonal anti-CD31 antibody (Santa Cruz 
Biotechnology, sc-1506, final concentration 
2ng/µl) and ImmPRESS Reagent anti-goat Ig 
peroxidase (Vector Laboratories) were used. 
Negative controls were performed by replacing 
primary antibody with normal goat 
immunoglobulins. Then, the CD31 positive 
regions (in brown) were quantified using ImageJ 
1.43 and vascularity density was calculated as 
the percent of tumor tissue area occupied by 
vessels as described (24). 
Analysis of Data. Data are given as the mean ± 
SEM. Differences of formed tumors in response 
to saline or pNaKtide were calculated with chi-
square test. One-way ANOVA test was used to 
test the significance in tumor weights and tumor 
volumes. Statistical significance of data from all 
other experiments was determined by Student’s 
t-test. A p value of <0.05 was considered to be 
significant. 
 
Results 
 
Down-regulation of α1 Na/K-ATPase in prostate 
cancer. As depicted in Figs. 1A and B, the 
expression of α1 Na/K-ATPase is significantly 
reduced in human prostate carcinoma (PCa) as 
measured by IHC staining. While most of the 
control samples exhibited moderate to strong 
staining, more than 50% of PCa samples (20 
samples out of a total of 36) had a weak staining.  
Moreover, about 11% of samples (4 out of a 
total of 36) were actually scored absent for α1 
Na/K-ATPase.  To verify these findings and to 
establish an in vitro model for further 
investigation, we conducted the following 
studies in three human prostate cancer cell lines 
that exhibit different metastatic potentials (25).  
Normal human prostate epithelial RWPE-1 cells 
and LLC-PK1 cells, a non-cancerous renal 
epithelial cell line extensively used in our prior 
studies of Na/K-ATPase-mediated signal 
transduction (7,22), were used as controls. As 
shown in Fig. 1C, significant reduction in the 
total cellular α1 Na/K-ATPase was noted in 
DU145 and PC-3 cell lysates.  Because the α1 
Na/K-ATPase regulates mainly the plasma 
membrane, not cytoplasmic, pool of Src, we 
immunostained these cells with anti-α1 antibody 
and examined the cellular distribution of α1 
Na/K-ATPase. As depicted in Fig. 2A, the α1 
subunit mainly resided in the plasma membrane 
in control cell lines. This pool of 1 Na/K-
ATPase is significantly reduced in cancer cell 
lines. Quantitative analyses using line scanning 
reveal a reduction of about 15%, 50% and 75% 
in the plasma membrane area across the LNCaP, 
DU145 and PC-3 cells, respectively (Fig. 2B).  
These reductions were further confirmed by 
surface biotinylation assays (Fig. 2D). 
Interestingly, high level of diffused and vesicular 
α1 staining relative to the plasma membrane 
signal was noted in DU145 and PC-3 cells (Fig. 
2C) after increasing the laser intensity. These 
findings suggest an increased endocytosis of α1 
Na/K-ATPase in these cells. To further test this, 
a pulse-chase experiment was performed to 
directly measure the endocytosed α1 in DU145 
cells.  Surface-biotinylated cells were brought 
back to normal culture condition for different 
times, and then surface-bound biotin was cleared 
using TCEP. The remaining biotinylated 
intracellular pool of α1 was analyzed.  Because a 
large number of RWPE-1 cells detached from 
culture dish during TCEP treatment, LLC-PK1 
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cells were used as a control.  As shown in Fig. 
2E, there was no endocytosed α1 detected at 0 
min, suggesting that TCEP cleavage was 
complete. After recovery for 30 min, much more 
(about 3-times) α1 was endocytosed in DU145 
than that in LLC-PK1 cells. Considering the 
difference in the membrane α1 amount in these 
two cell lines (Fig. 2B and 2D), the α1 
endocytosis per 30 min in DU145 cells could be 
9-10 times of that in LLC-PK1 cells. 
As depicted in Fig. 3A, the amount of active 
Src or Src family kinases was significantly 
elevated in human cancer cells.  Because 
reduction of the α1 preferentially affects the Src-
interacting pool of Na/K-ATPase (11,21), this 
increase in Src activity could be due to the 
down-regulation of α1 Na/K-ATPase in these 
cells.  If this is a case, it is likely that addition of 
α1 mimetic peptide would be able to inhibit Src 
and then cancer cell growth.  To test this 
possibility, we transfected DU145 cells with 
YFP-ND1 and evaluated its effect on cell 
growth.  The ND1 peptide is derived from the N 
domain of 1 subunit (residues 379-435), and 
binds and inhibits Src (10). As depicted in Fig. 
S1A, the expression of YFP-ND1 was detected 
as early as 6 h post transfection and peaked at 24 
h in DU145 cells.  Notably, a significant 
decrease in the percentage of cells with YFP 
fluorescence was observed after 36 h in the 
YFP-ND1-transfected, but not YFP-transfected, 
cells. Moreover, a large number of YFP-ND1-
expressing cells rounded up and detached from 
the dish (Fig. S1A).  When Trypan Blue-
negative cells were counted, expression of YFP-
ND1 caused more than a 40% decrease in the 
number of cells (Fig. S1B).  Taken together, 
these findings indicate that the expression of 
ND1 has drastic effects on cell viability.  
 
pNaKtide attenuates activities of Src and Src 
effectors. In view of the above findings, we next 
tested whether the ND1-derived pNaKtide can 
inhibit activities of Src and Src effectors in 
human cancer cells.  As shown in Fig. 3A, 
pNaKtide had no effect on basal Src activity in 
LLC-PK1 cells as we previously reported (10).  
However, it caused a significant inhibition of the 
membrane pool of Src in all three cancer cell 
lines.  To confirm this finding, cell lysates from 
control and pNaKtide-treated DU145 cells were 
subjected to Western blot.  As depicted in Fig. 
3B, pNaKtide inhibited Src in DU145 cells.  
Moreover, pNaKtide inhibited known Src 
effectors such as FAK and ERKs in DU145 cells 
(Fig. 3B).  Finally, pNaKtide was also capable of 
reducing the expression of c-Myc (Fig. 3B) that 
is known to play an important role in prostate 
cancer development.  These data together 
indicate that pNaKtide could be used to attenuate 
the elevated activities of Src, Src effectors and c-
Myc in cancer cells.  It is important to note that 
pNaKtide is apparently specific to the α1-
interacting pool of Src because while pNaKtide 
had no effect on basal Src activity in LLC-PK1 
cells [Fig. 2A and Ref (10)], it did produce a 
significant inhibition  of Src in LLC-PK1-
derived TCN23-19 cells (Fig. S2) where the 
Na/K-ATPase-interacting pool of Src is freed by 
90% knockdown of the α1 subunit (11). 
 
Effects of pNaKtide on cell growth.  
Src is known to play an important role in 
regulating cell growth and apoptosis (12). We 
therefore evaluated the growth inhibitory effects 
of pNaKtide using MTT analysis. A time-
dependent growth inhibition in DU145 cells was 
presented in Fig. 4A.  It is important to note that 
pNaKtide also affected cell viability, which is 
apparent at higher concentrations (e.g. 1 and 5 
M).  When dose-dependent effects were 
measured in all three cancer cell lines, we found 
that LNCaP cells were most resistant to 
pNaKtide, whereas PC-3 cells were highly 
sensitive (Fig. 4B).  The EC50 value of pNaKtide 
was 100 nM, 5 µM and 20 µM in PC-3, DU145 
and LNCaP cells, respectively.  As a control, we 
repeated this set of experiments with pC1 (10). 
Like pNaKtide, pC1 is tagged with TAT leader 
sequence, and it is also distributed in the cell 
membrane (data not shown). We found that pC1 
did not have any inhibitory effect in the MTT 
assay up to 20 µM. 
Because pNaKtide affects cell viability, we 
tested whether pNaKtide stimulates apoptosis in 
DU145 cells using the following two sets of 
experiments. Staurosporine was used as a 
positive control. First, we measured the effect of 
pNaKtide on the cleavage of poly (ADP-ribose) 
polymerase (PARP) (26,27). As shown in Fig. 
5A, like staurosporine (STS), pNaKtide (1 and 5 
µM) stimulated PARP cleavage in DU145 cells. 
To verify the apoptotic effect of pNaKtide, 
annexin V/PI staining were performed. Like 
staurosporine, pNaKtide produced a clear 
membrane staining of annexin V without nuclear 
PI staining (Fig. 5B). 
 
pNaKtide Inhibits DU145 Xenograft Growth. 
Because the above in vitro studies indicate that 
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pNaKtide can inhibit Src/FAK/ERK and c-Myc 
pathways in human prostate cancer cells, we 
tested whether it would inhibit the tumor 
xenograft growth in vivo.  DU145 cells were 
chosen for the test because their sensitivity to 
pNaKtide is between PC-3 and LNCaP cells. In 
the first set of studies, cells were treated with 1 
µM pC1 or pNaKtide for 60 min and washed.  
Afterwards, 5 × 106 control peptide or 
pNaKtide-treated Trypan Blue-negative DU145 
cells were injected subcutaneously into 4-6 
week-old NOD/SCID mice.  We found that this 
treatment resulted in a significant reduction in 
tumor weight in vivo (tumor weight: pC1, 1.2 ± 
0.2 g, n=6, vs. pNaKtide, 0.6 ± 0.2 g, n=6; 
p<0.01) after 45 days.  However, this regimen of 
treatment is much less effective in inhibiting 
tumor growth than that of repeated dosing (see 
next paragraph). 
To test whether pNaKtide can reduce the 
growth or cause regression of an existing tumor, 
we used three groups of 4-6-week old 
NOD/SCID mice and injected them 
subcutaneously with 5 × 106 DU145 cells. The 
treatment with pNaKtide (in saline) or vehicle 
was initiated after the tumors reached an average 
volume of 100 mm3. As depicted in Figs. 6A, B 
and C, pNaKtide treatment produced a dose-
dependent inhibition of tumor growth.  When 10 
mg/kg pNaKtide was administered once every 
two days for five times, it resulted in over 75% 
inhibition in both tumor volume (Fig. 6D) and 
weight (Fig. 6B) even after stopping 
administration of pNaKtide for more than ten 
days. Moreover, half of tumors regressed after 
pNaKtide treatment and were not detected in 
final necropsy (Fig. 6B).  Interestingly, while 
two out of seven mice in the control group 
showed severe metastasis, none was detected in 
pNaKtide-treated groups.  
To test whether pNaKtide treatment affects 
Src expression and Src activity, we measured 
total Src and Src Y418 phosphorylation in the 
xenograft tumor homogenates. Consistent with 
the observation in cultured cells (Fig. 3), 
significant inhibition of Src was found in 
pNaKtide-treated tumor homogenates (Fig. 7A). 
However, pNaKtide treatment had no effect on 
the amount of total Src.   
Finally, we performed Hematoxylin & Eosin 
(H&E) staining of DU145 xenograft tumors.  As 
depicted in Fig. 7B, untreated tumors showed 
compact cell distribution patterns with dark blue 
nuclear staining in the vehicle group, suggesting 
that these tumor cells were highly proliferative. 
Accordingly, there were some cells with 
prominent nucleoli under stages of mitosis 
(arrowheads in Fig. 7B). Treatment with 
pNaKtide resulted in a decrease in cell 
population and cell division. In addition, more 
TUNEL-positive cells were found in pNaKtide-
treated tumors than that in control groups (Fig. 
7C).  
 
Inhibition of tumor angiogenesis by pNaKtide. 
Tumor growth and metastasis is highly 
dependent on angiogenesis (28). Interestingly, 
when tumors were collected from both control 
and pNaKtide-treated mice, we noticed that 
tumors in the pNaKtide-treated group were 
much paler than those from the control mice, 
suggesting that pNaKtide treatment might inhibit 
angiogenesis. To verify, we first assessed the 
effect of pNaKtide on the proliferation of 
cultured human endothelial cells since 
endothelial cell proliferation is the prerequisite 
of angiogenesis. As shown in Fig. 8A, pNaKtide 
inhibited the proliferation of both HUVEC and 
HAEC cells in a dose-dependent manner. To 
further test the ability of pNaKtide to inhibit in 
vivo angiogenesis, tumors from control and 
pNaKtide-treated animals were immunostained 
with an antibody against CD31 to identify 
vessels.  The vessel density of tumors from 
control mice was about 10% and pNaKtide 
treatment reduced the density to about 2.5% 
(Fig. 8B).  Moreover, when the production of 
vascular endothelial growth factor (VEGF, an 
angiogenic factor) was measured in tumor 
homogenates, we found that pNaKtide treatment 
produced more than 50% reduction in total 
VEGF (Fig. 8C).   Taken together, these findings 
indicate that pNaKtide inhibits tumor 
angiogenesis.   
 
Discussion 
 
In this report, we show that the plasma 
membrane pool of α1 Na/K-ATPase is 
significantly reduced in prostate cancer cells. We 
further demonstrate that supplement of the α1 
mimetic peptide (e.g., ND1 or pNaKtide) 
decreases activities of Src and Src effectors and 
consequently inhibits cancer cell growth.  
Furthermore, administration of pNaKtide 
potently inhibits the angiogenesis, stimulates 
apoptosis, and reduces the xenografted tumor 
size in the NOD/SCID mice.  These conclusions 
and other important issues are further discussed. 
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A potential role of Na/K-ATPase in 
regulation of tumor growth:  A decrease in α1 
Na/K-ATPase expression has been noted in 
several human cancers including pancreatic (29), 
colorectal (30), bladder (31) and kidney (32).  
Moreover, prior studies have also documented 
the down-regulation of β1 subunit of Na/K-
ATPase in several kidney cancer cell lines (33).  
We report here a significant reduction in α1 
Na/K-ATPase in human prostate carcinoma as 
well as in highly metastatic prostate cancer cell 
lines including DU145 and PC-3.  The most 
significant reduction in α(over 50%) was 
detected in the plasma membrane of these cells 
(Figs. 2A, 2B and 2D).   Moreover, we observed 
an increased endocytosis of α1 Na/K-ATPase in 
DU145 cells (Fig. 2E).  Thus, post-translational 
regulation may play an important role in the 
down-regulation of α1 Na/K-ATPase in these 
cells.  
Because prostate cancer cells, in general, do 
not need as much Na/K-ATPase to pump as do 
the normal epithelial cells, the observed down-
regulation of 1 Na/K-ATPase might be 
expected.  However, recent studies have 
revealed that the α1 Na/K-ATPase has many 
non-pumping functions that could play an 
important role in regulation of cell migration and 
growth. For example, the formation of tight 
junction in epithelia requires the expression of 
Na/K-ATPase (34).  Moreover, the β subunit is 
known to play an important role in cell/cell 
adhesion as well as cell/matrix interaction (35).  
Interestingly, repletion of β1 subunit appears to 
be sufficient to reduce the migration and tumor 
formation of kidney cancer cells (36).  
Furthermore, we have recently demonstrated an 
important role of Na/K-ATPase α1 subunit in 
regulation of cellular kinase activity through its 
interaction with c-Src in the plasma membrane 
(7,8,11,37).  Therefore, we suggest that the 
reduction in the plasma membrane α1 could 
affect the growth of tumor in several ways.  
First, the down-regulation of α1 Na/K-ATPase 
might make it less effective for Na/K-ATPase to 
interact with and then inhibit cellular Src. This 
would increase basal Src and FAK activity and 
consequently promote epithelial cell 
proliferation, migration and invasion (34,38,39).  
Consistently, we found that metastatic prostate 
cancer cells are highly sensitive to the addition 
of the Na/K-ATPase α1 mimetics, including 
ND1 (Fig. S1) and pNaKtide (Fig. 4). Second, a 
decrease in the plasma membrane Na/K-ATPase 
α1 would impair the ability of cells to provide a 
counter regulation of Src and other growth-
promoting pathways, especially in cellular 
structures such as tight junctions and adhesions 
where the Na/K-ATPase is highly concentrated 
in normal epithelial cells.  This could occur 
when cellular Src is activated by steroid 
hormone/receptor interaction (40,41) or other 
factors such as increased activity of HER (42).  
Finally, increases in Src activity due to the 
down-regulation of α1 could potentiate VEGF 
production and then promote angiogenesis.  
Needless to say, the potential role of Na/K-
ATPase in control of tumor growth needs to be 
further tested in animal models. 
The Na/K-ATPase as a target for 
developing novel anti-cancer therapeutics:  To 
our knowledge, this is the first report to show 
that α1 Na/K-ATPase mimetic peptides are 
effective in inducing apoptosis in prostate cancer 
cells (Fig. 5).  Moreover, two different sets of 
experiments demonstrate that pNaKtide is highly 
effective in blocking the growth of DU145 
xenograft in vivo.  First, we found that 
pretreatment of DU145 cells with pNaKtide 
caused a significant reduction in tumor size.  
Although it is unlikely that the activity of 
pNaKtide loaded into DU145 cells during one 
hour exposure would last for 45 days in vivo, its 
effects on cell growth during the first few days 
could produce this reduction in tumor size.  This 
mode of action has been demonstrated with other 
compounds (43). Second, we found that repeated 
dosing (once every two days for a total of five 
times) was more effective in reducing tumor size 
than that of one hour exposure.  Moreover, 
repeated dosing appears to be capable of 
inducing tumor regression and preventing tumor 
metastasis.  Of course, these effects need to be 
further verified.   
Mechanistically, pNaKtide stimulates 
apoptosis, inhibits cell growth, and decreases 
tumor angiogenesis (Figs. 4 and 8).  Some of 
these effects are likely related to the Src 
inhibitory action of pNaKtide.  However, 
pNaKtide is unique in the way it regulates 
cellular Src.  First, pNaKtide is not an ATP 
mimetic and thus works differently from this 
class of small molecular Src inhibitors (44-47).  
Second, it is derived from a widely expressed 
endogenous protein (10). Third, a majority of 
pNaKtide appears to be localized in the plasma 
membrane (10) where the active Src resides. 
This action mechanism explains why only 
marginal cellular Src activity is inhibited by 
pNaKtide (Fig. 3) in normal epithelial cells, 
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whereas small-molecule ATP mimetic produced 
a complete inhibition (44).  This is also 
consistent with the finding that pNaKtide is less 
effective in inhibiting the growth of LNCaP cells 
where a large pool of α1 Na/K-ATPase is 
expressed in the plasma membrane.  On the 
other hand, pNaKtide becomes highly effective 
for more metastatic cells such as DU145 and 
PC-3 where the plasma membrane pool of Na/K-
ATPase is significantly reduced (Fig. 2).  Thus, 
the effect of pNaKtide appears to be highly 
selective.   
Since peptides are normally vulnerable to 
peptidase degradation, more studies are needed 
to further characterize the stability of pNaKtide 
in vivo. Absorption and metabolism of pNaKtide 
in whole animals remain to be assessed. It would 
also be important to characterize the distribution 
and stability of pNaKtide in tumor samples.  
Nevertheless, our studies here clearly 
demonstrate the anticancer efficacy of pNaKtide 
in vivo.  Finally, it has not escaped our notice 
that increased expression of the Na/K-ATPase 
α1 could present another strategy to target the α1 
Na/K-ATPase-mediated signal transduction in 
cancer cells.  However, effective compounds 
remain to be discovered and tested. 
 
 
REFERENCES 
 
1. Kaplan, J. H. (2002) Annu Rev Biochem 71, 511-535 
2. Skou, J. C. (1957) Biochim Biophys Acta 23, 394-401 
3. Cai, T., Wang, H., Chen, Y., Liu, L., Gunning, W. T., Quintas, L. E., and Xie, Z. J. 
(2008) J Cell Biol 182, 1153-1169 
4. Rajasekaran, A. K., and Rajasekaran, S. A. (2003) Am J Physiol Renal Physiol 285, 
F388-396 
5. Li, Z., and Xie, Z. (2009) Pflugers Arch 457, 635-644 
6. Tian, J., and Xie, Z. J. (2008) Physiology (Bethesda) 23, 205-211 
7. Tian, J., Cai, T., Yuan, Z., Wang, H., Liu, L., Haas, M., Maksimova, E., Huang, X. 
Y., and Xie, Z. J. (2006) Mol Biol Cell 17, 317-326 
8. Chen, Y., Cai, T., Wang, H., Li, Z., Loreaux, E., Lingrel, J. B., and Xie, Z. (2009) J 
Biol Chem 284, 14881-14890 
9. Ye, Q., Li, Z., Tian, J., Xie, J. X., Liu, L., and Xie, Z. (2011) J Biol Chem 286, 6225-
6232 
10. Li, Z., Cai, T., Tian, J., Xie, J. X., Zhao, X., Liu, L., Shapiro, J. I., and Xie, Z. (2009) 
J Biol Chem 284, 21066-21076 
11. Liang, M., Cai, T., Tian, J., Qu, W., and Xie, Z. J. (2006) J Biol Chem 281, 19709-
19719 
12. Thomas, S. M., and Brugge, J. S. (1997) Annu Rev Cell Dev Biol 13, 513-609 
13. Yeatman, T. J. (2004) Nat Rev Cancer 4, 470-480 
14. Irby, R. B., and Yeatman, T. J. (2000) Oncogene 19, 5636-5642 
15. Ma, Y. C., Huang, J., Ali, S., Lowry, W., and Huang, X. Y. (2000) Cell 102, 635-646 
16. Migliaccio, A., Castoria, G., Di Domenico, M., de Falco, A., Bilancio, A., Lombardi, 
M., Barone, M. V., Ametrano, D., Zannini, M. S., Abbondanza, C., and Auricchio, F. 
(2000) EMBO J 19, 5406-5417 
17. Kaplan, K. B., Swedlow, J. R., Varmus, H. E., and Morgan, D. O. (1992) J Cell Biol 
118, 321-333 
18. Kaplan, K. B., Bibbins, K. B., Swedlow, J. R., Arnaud, M., Morgan, D. O., and 
Varmus, H. E. (1994) EMBO J 13, 4745-4756 
19. Wang, Y., Botvinick, E. L., Zhao, Y., Berns, M. W., Usami, S., Tsien, R. Y., and 
Chien, S. (2005) Nature 434, 1040-1045 
20. Sandilands, E., Brunton, V. G., and Frame, M. C. (2007) J Cell Sci 120, 2555-2564 
9 
 
21. Liang, M., Tian, J., Liu, L., Pierre, S., Liu, J., Shapiro, J., and Xie, Z. J. (2007) J Biol 
Chem 282, 10585-10593 
22. Haas, M., Wang, H., Tian, J., and Xie, Z. (2002) J Biol Chem 277, 18694-18702 
23. Gottardi, C. J., Dunbar, L. A., and Caplan, M. J. (1995) Am J Physiol 268, F285-295 
24. Wang, G. M., Kovalenko, B., Wilson, E. L., and Moscatelli, D. (2007) Prostate 67, 
968-975 
25. Aalinkeel, R., Nair, M. P., Sufrin, G., Mahajan, S. D., Chadha, K. C., Chawda, R. P., 
and Schwartz, S. A. (2004) Cancer Res 64, 5311-5321 
26. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, 
M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., and et al. (1995) Nature 
376, 37-43 
27. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. 
(1994) Nature 371, 346-347 
28. Folkman, J. (2006) Annu Rev Med 57, 1-18 
29. Yamanaka, Y., Onda, M., Uchida, E., Yokomuro, S., Hayashi, T., Kobayashi, T., 
Sasajima, K., Shirota, T., Tajiri, T., Egami, K., and et al. (1989) Nippon Ika Daigaku 
Zasshi 56, 579-583 
30. Sakai, H., Suzuki, T., Maeda, M., Takahashi, Y., Horikawa, N., Minamimura, T., 
Tsukada, K., and Takeguchi, N. (2004) FEBS Lett 563, 151-154 
31. Espineda, C., Seligson, D. B., James Ball, W., Jr., Rao, J., Palotie, A., Horvath, S., 
Huang, Y., Shi, T., and Rajasekaran, A. K. (2003) Cancer 97, 1859-1868 
32. Seligson, D. B., Rajasekaran, S. A., Yu, H., Liu, X., Eeva, M., Tze, S., Ball, W., Jr., 
Horvath, S., deKernion, J. B., and Rajasekaran, A. K. (2008) J Urol 179, 338-345 
33. Rajasekaran, S. A., Ball, W. J., Jr., Bander, N. H., Liu, H., Pardee, J. D., and 
Rajasekaran, A. K. (1999) J Urol 162, 574-580 
34. Rajasekaran, S. A., Hu, J., Gopal, J., Gallemore, R., Ryazantsev, S., Bok, D., and 
Rajasekaran, A. K. (2003) Am J Physiol Cell Physiol 284, C1497-1507 
35. Barwe, S. P., Anilkumar, G., Moon, S. Y., Zheng, Y., Whitelegge, J. P., Rajasekaran, 
S. A., and Rajasekaran, A. K. (2005) Mol Biol Cell 16, 1082-1094 
36. Inge, L. J., Rajasekaran, S. A., Yoshimoto, K., Mischel, P. S., McBride, W., Landaw, 
E., and Rajasekaran, A. K. (2008) Histol Histopathol 23, 459-467 
37. Ferrandi, M., Molinari, I., Barassi, P., Minotti, E., Bianchi, G., and Ferrari, P. (2004) 
J Biol Chem 279, 33306-33314 
38. Rajasekaran, S. A., Barwe, S. P., Gopal, J., Ryazantsev, S., Schneeberger, E. E., and 
Rajasekaran, A. K. (2007) Am J Physiol Gastrointest Liver Physiol 292, G124-133 
39. Contreras, R. G., Shoshani, L., Flores-Maldonado, C., Lazaro, A., and Cereijido, M. 
(1999) J Cell Sci 112 ( Pt 23), 4223-4232 
40. Desai, S. J., Ma, A. H., Tepper, C. G., Chen, H. W., and Kung, H. J. (2006) Cancer 
Res 66, 10449-10459 
41. Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., 
Melamed, J., Handratta, V. D., Njar, V. C., Brodie, A. M., Yu, L. R., Veenstra, T. D., 
Chen, H., and Qiu, Y. (2006) Cancer Cell 10, 309-319 
42. Ishizawar, R., and Parsons, S. J. (2004) Cancer Cell 6, 209-214 
43. Gilbert, C. A., Daou, M. C., Moser, R. P., and Ross, A. H. (2010) Cancer Res 70, 
6870-6879 
44. Chang, Y. M., Bai, L., Liu, S., Yang, J. C., Kung, H. J., and Evans, C. P. (2008) 
Oncogene 27, 6365-6375 
45. Lara, P. N., Jr., Longmate, J., Evans, C. P., Quinn, D. I., Twardowski, P., Chatta, G., 
Posadas, E., Stadler, W., and Gandara, D. R. (2009) Anticancer Drugs 20, 179-184 
10 
 
46. Tatarov, O., Mitchell, T. J., Seywright, M., Leung, H. Y., Brunton, V. G., and 
Edwards, J. (2009) Clin Cancer Res 15, 3540-3549 
47. Rabbani, S. A., Valentino, M. L., Arakelian, A., Ali, S., and Boschelli, F. (2010) Mol 
Cancer Ther 9, 1147-1157 
 
FOOTNOTES 
 
*We thank Dr. Guiyuan Li at University of Toledo for assistance with pathological studies and Ms 
Martha Heck for editing the manuscript. This work was supported by the National Heart, Lung and 
Blood Institute grant HL-36573 and the National Institute of General Medical Sciences grant GM-
78565. 
 
The abbreviations used are: CTS, cardiotonic steroids; EYFP, enhanced yellow fluorescent protein; 
ERK, extracellular signal-regulated protein kinase; FAK, focal adhesion kinase; HAEC, human aortic 
endothelial cells; HUVEC, human umbilical vein endothelial cells; PARP, Poly (ADP-ribose) 
Polymerase; PCa, prostate carcinoma; PI3K, phosphoinositide 3-kinase; VEGF, vascular endothelial 
growth factor. 
 
FIGURE LEGENDS 
 
Figure 1. Downregulation of α1 Na/K-ATPase in prostate cancer cells. A, α1 expression patterns 
in paired human normal prostate tissue (left in A) and carcinoma (right in A). Human tissue arrays 
were immunostained with monoclonal antibody against α1 (in brown). Hematoxylin was used for 
counterstaining of cell nucleus (in blue). B, α1 staining score in prostate tissues. Staining intensity was 
scored as absent (0), weak (1), moderate (2), or strong (3). Two independent pathologists scored each 
slide three times. C, Expression of Na/K-ATPase α1 subunit in cultured cells. Equal amount of whole 
cellular proteins (20 µg) from confluent cells were subject to Western blot analysis with the anti-α1 
antibody. The upper panel shows representative blots of α1 and GAPDH, and the lower panel shows 
the quantification data of α1 intensity from four independent experiments. *, p<0.05; **, p<0.01. 
 
Figure 2. Decreases in surface expression of α1 Na/K-ATPase in prostate cancer cells. A, Cellular 
distribution of α1 Na/K-ATPase. The fixed cells were immunostained with anti-α1 antibody and 
visualized (in Red) with a Leica DMIRE2 confocal microscope. Representative images from four 
independent experiments are shown. The scale bar represents 5 µm. B, Line scan quantitation of α1 
staining intensity across the cell membrane. The α1 intensity was line-scan quantified using ImageJ. X 
axis is defined as distance (in pixel unit) from cell membrane where the highest α1 staining intensity 
is. Y axis is the arbitrary unit of quantified staining intensity within each pixel unit. Thirty individual 
cells from three separate experiments were used to collect these data. C, Cellular distribution of α1 in 
DU145 and PC-3 cells after higher intensity laser was applied. The scale bar represents 8 µm. D, Cell 
surface α1 in cultured cells. Biotinylated cell surface proteins were analyzed for α1 by Western blot. 
Representative blots from three independent experiments are shown. E, Endocytosed α1 in cultured 
cells. The upper panel depicts a typical immunoblot of biotinylated α1 Na/K-ATPase after 0 and 30 
min recovery. The assays were conducted as described in “Experimental Procedures”. Quantified data 
from three independent experiments are shown in the lower panel as relative to LLC-PK1.  p<0.05; 
**, p<0.01. 
 
Figure 3. Effects of α1 mimetics on Src signaling in DU145 cells. A, Active Src in control or 
pNaKtide-treated (1 µM for 1 h) cells. Cells on coverslips were fixed with ice-cold methanol, then 
immunostained using anti-pY418 antibody. Fluorescence of Src pY418 was visualized (in Green) 
with a Leica DMIRE2 Confocal Microscope. Representative images from three separate experiments 
are shown.  The scale bar represents 5 µm. B, Regulation of Src and Src effectors by pNaKtide. 
DU145 cells were exposed to pNaKtide at indicated concentrations for 1 h. Cell lysates were analyzed 
for Src, ERK, and FAK phosphorylation as well as c-Myc by Western blot. Representative blots from 
three independent experiments are shown. 
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Figure 4. Effect of pNaKtide on DU145 cell proliferation. Cells were seeded in 96-well plates and 
exposed to pNaKtide as the function of times (A) or doses (B). MTT assay was performed according 
to the instructions from ATCC. n=4.  
 
Figure 5. Induction of apoptosis by pNaKtide in DU145 cells. A, PARP cleavage induced by 
pNaKtide. The DU145 cells were exposed to pNaKtide or 0.5 µM staurosporine (STS) for 24 h. The 
attached and detached cells from the culture media were collected and analyzed for PARP by Western 
blot. Representative blots from three independent experiments are shown. B, Annexin V/PI staining of 
DU145 cells in the absence or presence of pNaKtide. Upon treatment, DU145 cells were stained with 
annexin V and counterstained with PI using the Vybrant Apoptosis Kit.  Annexin V (in green) and PI 
(in red) were visualized using a Leica DMIRE2 confocal microscope. Representative images of four 
independent studies are shown. The scale bar represents 8 µm.  
 
Figure 6. Effect of pNaKtide on the growth of DU145 xenografts in NOD/SCID mice. DU145 
cells (5  106) were s.c. injected in the flank of NOD/SCID mice. After mean tumor volume reached 
100 mm3, mice were injected with saline or pNaKtide at a dose of 2 mg/kg or 10 mg/kg. A, Average 
body weight of the NOD/SCID mice after administration of pNaKtide. B, Tumor formation in 
NOD/SCID mice. The average tumor weight values were from 4 and 6 tumors of 2 mg/kg and 10 
mg/kg pNaKtide-treated groups, respectively. C, Mice bearing xenograft tumors. Arrowheads 
identified the location of the tumors. D, Growth of DU145 xenograft tumors in NOD/SCID mice 
treated with saline or pNaKtide. *, p<0.05; **, p<0.01. 
 
Figure 7. Characterization of xenograft tumors. Fourteen tumors in saline group and six tumors in 
10 mg/kg pNaKtide group were analyzed herein. A, Effects of pNaKtide on Src. Tumor homogenates 
from saline and pNaKtide groups were analyzed for total Src and Src pY418 by Western blot. 
Quantitative data were collected as the pY418/Src ratio from tumor samples. B, H&E staining of the 
formalin-fixed, paraffin-embedded xenograft tumors. Original magnifications, × 600. Arrowheads 
indicate cells in mitosis. C, TUNEL assay of xenograft tumors. TUNEL assay was performed using 
the TUNEL Apoptosis Detection Kit and percent of TUNEL-positive cells was quantified. **, p<0.01. 
 
Figure 8. Effects of pNaKtide on angiogenesis. A, Inhibition of endothelial cell proliferation by 
pNaKtide. HUVEC / HAEC cells cultured in 12-well plates were exposed to pNaKtide at indicated 
concentrations for 72 h. Then, Trypan Blue-negative cells were counted. Data from four independent 
experiments were collected. B, Vessel density of xenograft tumors. IHC staining of CD31 in the 
formalin-fixed, paraffin-embedded xenograft tumors (14 in saline group and 6 in 10 mg/kg pNaKtide 
group) was performed to identify the vessels. Then, the vessel density was calculated as the percent of 
tumor area occupied by vessels. C, Expression of VEGF in tumor homogenates. VEGF levels in the 
saline or pNaKtide-treated tumors were evaluated by Western blot using the anti-VEGF antibody. *, 
p<0.05; **, p<0.01. 
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Figure 2 
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Figure 4  
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Figure 5 
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Administration Tumors Formed/ Injection Sites
Tumor 
Weight (g)
Saline 14/14 1.1 ±0.3
pNaKtide 2mg/Kg 4/6 0.7 ±
 
0.3*
pNaKtide 10mg/Kg 6/12** 0.3 ±0.3**
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